Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Oncotarget|June 11, 2016
Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancerLichao Sun, Joseph Burnett, Mari Gasparyan, et al.
Cancer Letters|September 7, 2024
Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancerMaría Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2021
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER<sup>+</sup> Breast CancerAlberto Servetto, Rahul Kollipara, Luigi Formisano, et al.
Nature Communications|October 31, 2020
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancerKyung-Min Lee, Angel L Guerrero-Zotano, Alberto Servetto, et al.
Cancer Cell|June 25, 2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivityAriella B Hanker, Benjamin P Brown, Jens Meiler, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Plos One|October 11, 2012
R26R-GR: a Cre-activable dual fluorescent protein reporter mouseYou-Tzung Chen, Ming-Shian Tsai, Tsung-Lin Yang, et al.
Ebiomedicine|June 27, 2025
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerMaxwell R Lloyd, Rosario Chica-Parrado, Caroline M Weipert, et al.
Pageof 4